KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial.

Do-Youn Oh, Masafumi Ikeda, Choong-Kun Lee, Carlos Rojas, Chih-Hung Hsu, Jin Won Kim, Lin Shen, Junji Furuse, Joon Oh Park, Mitesh Borad, Filippo de Braud, John Bridgewater, Sunyoung S Lee, Markus Moehler, Francois Audhuy, Motonobu Osada, Masashi Sato, Changhoon Yoo

Hepatology 81(3) 823-836

PMID38875119
PMCIDPMC11825481
DOI10.1097/HEP.0000000000000965
发表日期2024-06-14
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:图像复核确认至少一个 KM 面板含可见 No. at risk 表。
摘要

摘要

BACKGROUND AND AIMS: We compared the safety and efficacy of bintrafusp alfa (BA) in combination with gemcitabine+cisplatin (GemCis), to those of GemCis alone, in patients with biliary tract cancer. APPROACH AND RESULTS: This randomized, double-blind, placebo-controlled, adaptive design phase 2/3 trial (NCT04066491) included adults who are treatment-naive with locally advanced/metastatic biliary tract cancer. Patients (N = 297) were randomized to receive an IV infusion of BA (2400 mg once/3 wk) plus GemCis (gemcitabine 1000 mg/m 2 +cisplatin 25 mg/m 2 on days 1 and 8/3 wk; 8 cycles) (BA group, n = 148) or placebo+GemCis (placebo group, n = 149). The primary end point was overall survival (OS). For adaptation analysis (phase 2-phase 3; data cutoff: May 20, 2021), efficacy was assessed in the first 150 patients who were antibiotic-naive when 80 progression-free survival events had occurred and ≥ 19 weeks of follow-up had been completed (BA, n = 73; placebo, n = 77). Median OS (95% CI) for the BA (11.5 mo [9.3-not estimable]) and placebo (11.5 mo [10.0-not estimable]) groups was comparable (hazard ration 1.23 [95% CI 0.66-2.28]; p = 0.7394); OS data maturity was 27.2% (41 events/151 patients). The most common grade ≥3 treatment-related adverse event was anemia (BA, 26.0%; placebo, 22.8%). Bleeding adverse events were reported more frequently in the BA group (28.8%) versus the placebo group (7.4%). Deaths within 60 days of the first dose were reported in 7.5% and 1.3% of patients in the BA and placebo groups, respectively. CONCLUSIONS: BA+GemCis did not provide a clinically meaningful benefit compared with GemCis alone as first-line treatment for biliary tract cancer, and the study was discontinued early (terminated: August 20, 2021).

KM 提取结果

2 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure1 个面板

FIGURE 2

FIGURE 2 Overall survival (primary end point)—randomized double-blind phase. Abbreviations: GemCis, gemcitabine+cisplatin; NE, not estimable; OS, overall survival.

Figure_2

Overall survival

FIGURE 2 · Panel Figure_2

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Figure_2 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure1 个面板

FIGURE 3

FIGURE 3 Progression-free survival according to RECIST v1.1 (as adjudicated by the IRC). Abbreviations: GemCis, gemcitabine+cisplatin; IRC, Independent Review Committee; RECIST, Response Evaluation Criteria in Solid Tumors.

Progression-free_survival

Progression-free survival

FIGURE 3 · Panel Progression-free_survival

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Progression-free_survival 是同一 FIGURE 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

captionless-figureGraphical abstract
非 KM Figure
FIGURE 1FIGURE 1 Trial profile. Abbreviations: AE, adverse event; GemCis, gemcitabine+cisplatin; PD, progressive disease.
非 KM Figure
FIGURE 4FIGURE 4 Waterfall plot (A and B) and Spider plot (C and D) of percent change (from baseline) in the sum of diameters of all target lesions. Abbreviations: CR, complete response; GemCis, gemcitabine+cisplatin; IRC, Independent Review Committee; NE, not estimable; PD, progressive disease; PR, partial response; RECIST, Response Evaluation Criteria in Solid Tumors.
非 KM Figure